Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Article 2025 en
Authors
PR
Paul G. Richardson
EO
Elisabeth K. O’Donnell
PO
Peter O’Gorman
Abstract
1 min read
Supported by multiple lines of high-level evidence, isatuximab in combination with standard-of-care backbone therapies produces triplet or quadruplet regimens with enhanced efficacy and consistent safety for the treatment of patients with NDMM and RRMM.
Paul G. Richardson, Antonio Palumbo, Stephen Schey, Meletios A Dimopoulos, Thierry Façon, Katja Weisel, Peter O’Gorman, Xavier Leleu, Martha Q. Lacy, Matthew Streetly, Joseph Mıkhael, David S. Siegel, Jesús F. San Miguel, Kenneth C. Anderson
Meletios A Dimopoulos, Andrzej Jakubowiak, Philip L. McCarthy, Robert Z. Orlowski, Michel Attal, Joan Bladé, Hartmut Goldschmidt, Katja Weisel, Karthik Ramasamy, Sonja Zweegman, Andrew Spencer, Jeffrey Huang, Jin Lu, Kazutaka Sunami, Shinsuke Iida, Wee Joo Chng, Sarah A. Holstein, Alberto Rocci, Tomáš Skácel, Richard Labotka, Antonio Palumbo, Kenneth C. Anderson
Meletios A Dimopoulos, Sara Galimberti, P. Anttila, Marcelo Capra, Michèle Cavo, Craig E. Cole, Cristina Gasparetto, Vânia Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yañez Ruiz, Jian Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij
Discussion(0)
No comments yet. Be the first to comment.